149741-42-4

Basic information

• Product Name: 3-[2-(4-aminophenyl)ethyl]-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione
• Synonyms: 1H-purine-2,6-dione, 3-[2-(4-aminophenyl)ethyl]-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,9-dihydro-1-propyl-; 3-[2-(4-aminophenyl)ethyl]-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1-propyl-3,9-dihydro-1H-purine-2,6-dione
• CAS NO: 149741-42-4
• Molecular Formula: C₂₅H₃₁N₅O₂
• Molecular Weight: 433.5459
• Mol File: 149741-42-4.mol

Chemical Properties

• Boiling Point: 706.6°C at 760 mmHg
• Flash Point: 381.1°C
• Density: 1.318g/cm³
• Vapor Pressure: 8.18E-20mmHg at 25°C
• Refractive Index: 1.66
• CAS DataBase Reference: 3-[2-(4-aminophenyl)ethyl]-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(4-aminophenyl)ethyl]-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione(149741-42-4)
• EPA Substance Registry System: 3-[2-(4-aminophenyl)ethyl]-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione(149741-42-4)

Safety Data

• Hazardous Substances Data: 149741-42-4(Hazardous Substances Data)

Upstream product

• 16200-53-6 3-noradamantanecarboxylic acid 
• 149340-98-7 6-amino-1-<4-<(benzyloxycarbonyl)amino>phenethyl>-5-nitroso-3-propyluracil 
• 149340-99-8 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil 
• 149340-97-6 6-amino-1-<4-<(benzyloxycarbonyl)amino>phenethyl>-3-propyluracil 
• 149340-95-4 6-amino-1-(4-nitrophenethyl)-3-propyluracil 
• 149340-94-3 1-(cyanoacetyl)-3-(4-nitrophenethyl)-1-propylurea 
• 149340-96-5 6-amino-1-(4-aminophenethyl)-3-propyluracil 
• 149340-93-2 1-(4-nitrophenethyl)-3-propylurea 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 
• 149741-55-9 6-amino-1-(4-aminophenethyl)-5-<(3-noradamantylcarbonyl)amino>-3-propyluracil 

Relevant articles and documents

Xanthine derivatives

A novel xanthine derivative of the formula (I): STR1 wherein one of R1 and R2 represents substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted alicyclic alkyl, substituted or unsubstitut

Xanthine derivatives

A xanthine derivative of the formula (I): STR1 wherein R1 represents substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted alicyclic alkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl; R2 represents --(CH2)m --X, wherein m is 2 or 3, and X is STR2 wherein a is NH, O or S, b and d are the same or different and are CH or N, and R3 is lower alkyl, substituted or unsubstituted alicyclic alkyl, or substituted or unsubstituted phenyl, or STR3 wherein e, g and h are the same or different and are CH or N, and R3 is the same as defined above; Q represents substituted or unsubstituted alicyclic alkyl, STR4 wherein R4 and R5 are the same or different and are substituted or unsubstituted alicyclic alkyl, STR5 wherein Y is single bond or alkylene; and n is 0 or 1, STR6 wherein K-M is --CH2 --CH2 --or --CH=CH--, and Y is the same as defined above, or STR7 wherein Y is the same as defined above; or a pharmacologically acceptable salt thereof is disclosed. This derivative has anti-dementia activity.

Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.

The effects of a variety of adenosine A1 and A2 antagonists on N6-((R)-phenylisopropyl)adenosine (R-PIA)- and scopolamine-induced amnesias were investigated in rodents in order to clarify the role of adenosine receptors in learning and memory. Some of the